mRNA vaccines are a type of vaccine designed to stimulate the immune system and provide protection against specific diseases. Traditional vaccines are generally suspensions of active (live) or inactivated microorganisms, toxins, or other disease-causing entities that are introduced into the body to trigger an immune response.
In conventional vaccination, weakened or inactivated components of pathogens, or their antigenic proteins, activate the immune system without causing the actual disease. This allows the immune system to safely recognize and respond to the foreign substance.
Once the immune system has been activated by these traditional vaccine components, it develops immunological memory. During any later exposure to the same pathogen, the immune system is able to recognize the antigen quickly and mount a faster and more effective defense against infection.
mRNA vaccines work differently from traditional vaccines because they do not contain live or inactivated pathogens, toxins, or pre-formed antigenic proteins.
Instead, mRNA vaccines use messenger RNA (mRNA), which is a genetic molecule that carries instructions for protein synthesis within cells.
The mRNA delivered through the vaccine provides instructions to the body’s immune cells, directing them to produce a specific antigen associated with the target pathogen.
Once this antigen is produced inside the body, it is recognized as foreign by the immune system, which then activates immune responses against it.
In response to the detected antigen, the immune system produces antibodies that are specifically targeted against that antigen.
These antibodies play a crucial role in providing targeted immune protection during any future exposure to the same antigen or pathogen.
During subsequent contact with the same pathogen, the immune system can rapidly identify the antigen and launch an efficient immune response, helping to prevent or reduce the severity of disease.
A major distinction between mRNA vaccines and traditional vaccines is that traditional vaccines directly introduce weakened pathogens, inactivated pathogens, or antigenic proteins into the body, whereas mRNA vaccines only provide the genetic instructions needed for the body’s own cells to produce the antigen.
Therefore, rather than supplying the antigen itself, mRNA vaccines rely on the body’s cellular machinery to generate the antigen internally, which then stimulates the immune system to develop protective immunity.
History and Development of mRNA Vaccine Technology
The history and development of mRNA vaccine technology began with the discovery of messenger RNA (mRNA) in 1961, when it was identified as the intermediate molecule that carries genetic information from DNA for protein synthesis. This discovery provided the essential theoretical foundation for the modern development of mRNA-based medical and vaccine technologies.
The first major step toward the practical application of mRNA occurred in 1989, when Robert Malone and his research team demonstrated that mRNA enclosed within a liposomal nanoparticle could be successfully transfected into eukaryotic cells. This experiment showed that mRNA could be delivered into cells and used to direct protein production.
Soon after, another important milestone was achieved when direct intramuscular injection of naked mRNA into mice resulted in detectable protein expression. This provided the first experimental evidence that in vitro transcribed (IVT) mRNA could successfully deliver genetic information into living organisms without requiring a viral or other delivery vector.
In 1993, the immunological basis of mRNA vaccines was established through studies showing that liposome-encapsulated mRNA encoding the nucleoprotein of the influenza virus could induce T-cell immune responses. This was a significant breakthrough because it demonstrated that mRNA could stimulate cellular immunity, which is essential for protection against many infectious diseases.
In 1995, further research confirmed that mRNA was also capable of stimulating humoral immunity. This meant that mRNA-based approaches could trigger the production of antibodies in addition to T-cell responses, making mRNA a highly promising platform for vaccine development.
A major scientific breakthrough occurred in 2005 when Katalin Karikó and Drew Weissman discovered that nucleoside modification, specifically replacing uridine with pseudouridine, significantly reduced immune recognition and unwanted immunogenicity while improving the translational efficiency of mRNA.
This discovery solved one of the major limitations of earlier mRNA technologies by making synthetic mRNA more stable, less inflammatory, and more effective for therapeutic applications.
The significance of this breakthrough was recognized globally, and this work was awarded the 2023 Nobel Prize in Physiology or Medicine.
Following this advancement, the commercial development of mRNA vaccine technology accelerated in the years that followed.
During this period, major improvements in lipid nanoparticle-based delivery systems further strengthened the potential of mRNA vaccines by enabling safer and more efficient delivery of mRNA into target cells.
These technological advancements laid the foundation for large-scale vaccine development and practical clinical use.
In 2020, mRNA vaccines encoding the spike protein of COVID-19 were rapidly designed in response to the global pandemic.
These vaccines later demonstrated excellent results in clinical trials, showing high efficacy in preventing severe disease and infection.
Real-world practical applications further confirmed their effectiveness, safety, and scalability, marking one of the most significant achievements in modern vaccine development.
The success of mRNA vaccines during the COVID-19 pandemic greatly accelerated global scientific interest and investment in mRNA research.
As a result, ongoing research is now focused on developing newer mRNA-based vaccines and therapeutics for a wide range of infectious diseases, cancers, and other medical conditions, indicating that mRNA technology continues to evolve rapidly.
Structure and Components of mRNA Vaccines
In an mRNA vaccine, the mRNA is engineered to resemble a fully processed mature mRNA, similar to how it naturally occurs in cells.
The Open Reading Frame (ORF), also called the coding sequence, is the core active component of mRNA.
It contains the genetic instructions to encode the protein of interest, which acts as an antigen for the immune system.
The ORF is flanked by two untranslated regulatory regions called the 5’ and 3’ Untranslated Regions (UTRs).
These UTRs increase mRNA stability and improve translation efficiency.
The 5’ cap is a methylated guanosine nucleotide attached to the 5’ end through a triphosphate linkage.
It is important for ribosomal recognition of mRNA, initiation of translation, and protection against degradation by exonucleases.
The poly-A tail is a long sequence of 50–250 adenine nucleotides present at the 3’ end.
It protects mRNA from exonucleolytic degradation and enhances translation efficiency.
The length of the poly-A tail influences mRNA half-life and translation initiation efficiency.
Delivery systems such as lipid nanoparticles (LNPs) or polymer-based vehicles are used to encapsulate mRNA.
These systems protect mRNA from degradation by extracellular ribonucleases.
They also facilitate efficient entry of mRNA into cells for antigen production.
How mRNA Vaccines Work in the Immune System
The working mechanism of mRNA vaccines involves several cellular and immunological processes that occur after vaccine administration.
After intramuscular injection, the encapsulated mRNA enters the body and is taken up by host cells, mainly myocytes and dendritic cells.
The plasma membrane of these cells invaginates and engulfs the mRNA-containing lipid nanoparticles through endocytosis, forming structures called endosomes.
Once inside the cell, endosomal escape occurs.
The lipids of the lipid nanoparticles (LNPs) destabilize the endosomal membrane, allowing the mRNA to escape into the cytoplasm.
In the cytoplasm, the released mRNA is recognized by cellular ribosomes.
The ribosomes translate the mRNA into the target protein, which acts as the antigen.
During this process, the mRNA does not enter the cell nucleus and does not interact with or alter the host genome.
After translation, the mRNA is naturally degraded by the host cell’s normal physiological processes.
The newly synthesized protein then undergoes proteasomal processing, where it is broken down into smaller peptide fragments in an ATP-dependent manner.
These peptide fragments (antigens) are presented on the surface of dendritic cells and macrophages, which act as antigen-presenting cells (APCs).
Antigen presentation occurs through MHC class I and MHC class II molecules.
This process activates both cytotoxic T-cells (CD8+) and helper T-cells (CD4+).
Activated helper T-cells stimulate the differentiation of B-lymphocytes into plasma cells.
These plasma cells produce and secrete antigen-specific antibodies, which contribute to humoral immunity.
At the same time, activated cytotoxic T-cells develop effector functions by releasing cytotoxic granules, interferons, and interleukins to destroy antigen-expressing cells.
This results in the activation of both humoral immunity and cell-mediated immunity.
After the primary immune response, memory B-cells and memory T-cells are formed.
These memory cells provide long-term immunological memory, enabling a faster and stronger immune response upon future exposure to the same pathogen.
Production and Manufacturing Process of mRNA Vaccines
The production and manufacturing process of mRNA vaccines begins with antigen selection and optimization.
First, the target antigen to be produced is identified.
The mRNA coding sequence for this antigen is then optimized using computational tools.
This optimization includes epitope selection, codon optimization, modification of untranslated regions (UTRs), and nucleoside modifications to achieve maximum stability and efficient protein expression.
The next step is DNA template synthesis.
After sequence optimization, a linear plasmid DNA or synthetic double-stranded DNA template encoding the optimized target mRNA sequence is produced.
This step is essential because RNA polymerases can only read DNA templates and transcribe them into mRNA.
The central step in mRNA vaccine manufacturing is in vitro transcription (IVT).
During IVT, the linearized DNA template is incubated with RNA polymerase, nucleotide triphosphates (NTPs), chemically modified nucleotides such as N1-methylpseudouridine (m1Ψ), and suitable reaction buffers for efficient enzymatic activity.
The RNA polymerase transcribes the DNA template into mRNA in a cell-free reaction system.
Large bioreactors are commonly used in this process to generate large quantities of mRNA within a short time.
After synthesis, the transcribed mRNA undergoes purification.
Purification is necessary to remove residual DNA, enzymes, and proteins that could trigger unintended immune responses.
Residual double-stranded DNA is first removed using DNase treatment.
Additional purification methods such as high-performance liquid chromatography (HPLC), affinity chromatography, or ion-exchange chromatography are used to obtain highly purified mRNA.
The purified mRNA is then subjected to encapsulation.
It is encapsulated within lipid nanoparticles (LNPs) to protect it and enable efficient cellular delivery.
LNP-mRNA formulations are prepared by rapidly mixing aqueous mRNA with an ethanolic lipid solution under controlled flow rates.
Differences in pH between the two flow states cause spontaneous self-assembly of lipid nanoparticles around the mRNA.
Following encapsulation, the mRNA-LNP product undergoes filtration.
Tangential flow filtration (TFF) is used to further purify the formulation.
This step removes ethanol, exchanges buffers, and eliminates non-encapsulated mRNA.
The purified product then moves to vaccine formulation and quality control.
The final vaccine is suspended in a compatible formulation buffer.
This buffer commonly contains sucrose, which helps maintain vaccine integrity during freezing and storage.
Before release for use, the final product undergoes strict quality control (QC) testing.
These tests confirm the vaccine’s integrity, sterility, purity, and potency to ensure safety and effectiveness.
Applications of mRNA Vaccines in Infectious Diseases
mRNA vaccines are being used for a wide range of infectious diseases, particularly life-threatening viral infections, due to their rapid development, flexibility, and strong immune response generation.
In influenza, mRNA-based vaccine candidates are designed to target the surface proteins of the influenza virus.
A major advantage of these vaccines is their ability to be rapidly updated according to circulating viral strains.
This is especially important in cases of antigenic drift and antigenic shift, which frequently occur in influenza viruses.
For Respiratory Syncytial Virus (RSV), mRNA vaccines have shown high efficacy in reducing RSV-associated lower respiratory tract disease (LRTD).
Since RSV is a major cause of respiratory infections, particularly in infants and older adults, mRNA vaccines offer a promising preventive approach.
In Human Immunodeficiency Virus (HIV) research, early-stage clinical trials of mRNA vaccines such as IAVI’s G001 and G002, and Moderna’s mRNA-1644, have demonstrated proof of concept for generating targeted antibodies against HIV.
These studies represent important progress toward the development of effective HIV vaccines.
For rabies, mRNA-based vaccines encoding the rabies glycoprotein RABV-G have shown the ability to induce both strong antibody responses and cell-mediated immune responses.
These responses have demonstrated advantages compared with traditional rabies vaccines.
Additional mRNA vaccine applications are being explored for the prevention and treatment of several other viral infections.
These include Zika virus infection, Cytomegalovirus infection, and Epstein-Barr virus infection.
The continued development of mRNA vaccines for these diseases highlights the broad therapeutic and preventive potential of mRNA vaccine technology in infectious disease control.
Role of mRNA Vaccines in COVID-19 Prevention
mRNA vaccines played a major role in the prevention and control of COVID-19, the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 uses its spike protein (S-protein) to interact with host cells, allowing viral attachment, fusion, and entry into the cell.
Because of its essential role in viral infection, the spike protein was identified as the primary target antigen for vaccine development against this pathogen.
mRNA vaccines developed against SARS-CoV-2 were specifically designed to encode the viral spike protein.
Once administered, these vaccines instruct host cells to produce the spike protein, which then triggers an immune response.
The immune system recognizes this protein as foreign and generates antibodies and cellular immune responses against it.
The first mRNA vaccines approved for widespread use were developed by Pfizer-BioNTech and Moderna.
These vaccines underwent rapid but extensive clinical trials involving thousands of participants within a year of development.
Clinical trial results demonstrated approximately 95% efficacy in preventing symptomatic COVID-19 in healthy adults.
This level of efficacy was significantly higher than that of many traditional vaccines.
In addition to preventing symptomatic infection, these vaccines showed strong protection against severe disease, hospitalization, and death.
During the global vaccination campaign, more than 13 billion vaccine doses were administered worldwide by 2022.
Epidemiological evidence showed that these vaccines saved millions of lives globally by significantly reducing infection rates and preventing severe outcomes.
The success of mRNA vaccines during the COVID-19 pandemic demonstrated the effectiveness, rapid scalability, and global public health importance of mRNA vaccine technology.
Advantages of mRNA Vaccines
Rapid development
Can be synthesized quickly once the target antigen sequence is known.
Allows rapid large-scale production.
Enables fast public health response against emerging pathogens.
Cell-free production
Produced through in vitro transcription (IVT).
Highly scalable manufacturing process.
Does not require live pathogens.
Avoids complex cell culture techniques.
Non-interacting with host genome
Functions only in the cytoplasm.
Does not enter the nucleus.
Naturally degraded after completing its function.
No integration into host DNA.
No risk of insertional mutagenesis.
Flexibility
Same manufacturing platform can be used for different pathogens.
Can target different antigens by changing the mRNA sequence.
Requires modification of only the encoding mRNA sequence.
Highly adaptable for future vaccine development.
Limitations of mRNA Vaccines
Thermostability issues
mRNA vaccines are highly susceptible to degradation
Require storage at very low temperatures (around -80°C)
Create logistical and transportation challenges
Difficult to distribute in areas with limited cold-chain infrastructure
Reactogenicity
Efficient delivery depends on lipid nanoparticle (LNP) formulations
LNPs may cause local reactogenicity, such as pain, redness, and swelling at the injection site
May also cause systemic reactogenicity, including fever, fatigue, and body aches in some recipients
Reduced antiviral antibody titers
Antiviral antibody levels may decline relatively quickly compared to some live vaccines
Titers can decrease within 2–3 months after vaccination
Often requires booster doses to maintain effective protection
Limited long-term data
mRNA vaccine technology is relatively new
Long-term immunological effectiveness still requires further study
More research is needed on durability of protection
Long-term safety profiles continue to be evaluated
Safety, Side Effects, and Effectiveness of mRNA Vaccines
mRNA vaccines undergo extensive evaluation through clinical trials and post-application pharmacovigilance programs to ensure their safety and effectiveness.
Large-scale clinical trials are conducted to establish an acceptable safety standard before authorization for public use.
If serious vaccine-related adverse effects are observed during clinical trials, the vaccine may fail to receive regulatory authorization.
Clinical evidence has shown that mRNA vaccines generally have a strong and acceptable safety profile.
Common local side effects include pain, rashes, lesions, redness, and swelling at the injection site.
Common systemic side effects include fatigue, headache, myalgia, fever, and chills.
These side effects are usually temporary, mild to moderate, and self-resolving without long-term complications.
Rare adverse events such as myocarditis and pericarditis have been reported.
These rare events have been observed mostly in younger males, particularly after receiving the second dose of certain mRNA vaccines, especially COVID-19 vaccines.
Despite rare adverse events, the overall benefits of vaccination generally outweigh the risks.
Data from both clinical trials and real-world applications have demonstrated the high effectiveness of mRNA vaccines.
These vaccines show strong protective and preventive efficiency against infectious diseases.
Their effectiveness has been demonstrated across multiple demographic groups and populations.
mRNA vaccines have also shown significant activity against emerging pathogens, highlighting their importance as a modern vaccine platform.
mRNA Vaccines vs. Traditional Vaccines
Traditional vaccines include live-attenuated, inactivated, and protein subunit vaccines.
These vaccines provide immunity by directly introducing the pathogen, pathogenic material, or isolated antigenic proteins into the body.
Their production requires pathogen culture, attenuation to remove pathogenicity, or isolation of specific proteins.
The manufacturing process is often complex and time-consuming for large-scale production.
Traditional vaccines may carry a risk of virulence, especially live-attenuated vaccines.
Inactivated and protein subunit vaccines are generally stable at refrigeration temperatures, making storage and transportation easier.
They also usually do not require multiple booster doses for long-term effectiveness.
mRNA vaccines, in contrast, work by providing genetic instructions for antigen production inside host cells.
They do not involve the use of live pathogens during manufacturing or application.
In mRNA vaccine development, the antigen sequence is first identified and then modified to produce the vaccine.
mRNA vaccines do not integrate into the host genome, so they have no risk of insertional mutagenesis.
After translation of the target antigen, the mRNA is naturally degraded by normal cellular processes.
mRNA vaccines offer faster and more flexible vaccine development compared to traditional vaccines.
However, they require ultra-low temperature storage and shipment, which creates logistical challenges.
They may also require continuous booster doses to maintain long-term effectiveness.
Future Prospects of mRNA Vaccine Technology
mRNA vaccine technology has promising future applications in personalized cancer treatment.
Personalized mRNA cancer vaccines can be designed using patient-specific tumor antigens.
These vaccines can stimulate immune responses that directly target and destroy tumor cells.
Ongoing advancements in lipid nanoparticle (LNP) formulations are focused on improving delivery efficiency.
Research is also aimed at enhancing the heat stability of mRNA vaccines.
Improved stability would increase storage life and reduce dependence on strict cold-chain systems.
This would make mRNA vaccines more accessible in regions with limited storage infrastructure.
Future mRNA vaccine development is focused on pathogens with high antigenic variability, such as influenza.
These vaccines can be rapidly updated to match emerging strains.
They may also be designed to target multiple strains simultaneously for broader immunity.
Another major advancement is the development of self-amplifying RNA (saRNA)-based vaccines.
These vaccines use viral replication machinery to amplify antigen production inside host cells.
As a result, they require lower vaccine doses.
They may also produce stronger and more durable immune responses compared to conventional mRNA vaccines.
Conclusion
mRNA vaccines have significantly transformed the field of immunization.
They have demonstrated high efficacy and safety in disease prevention.
Their success was clearly demonstrated through the widespread effectiveness of COVID-19 mRNA vaccines.
The ability to develop mRNA vaccines rapidly makes them highly valuable for responding to emerging global pathogens.
Their flexible and adaptable design supports rapid vaccine production during public health emergencies.
However, important limitations such as storage stability challenges and limited global accessibility still need to be addressed.
Continued advancements in mRNA vaccine technology are expected to overcome these challenges and expand their future applications.
References
World Health Organization (WHO). Vaccines and Immunization: What is Vaccination?
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—A new era in vaccinology. Nature Reviews Drug Discovery, 17, 261–279. https://doi.org/10.1038/nrd.2017.243
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019). Three decades of messenger RNA vaccine development. Nano Today, 28, 100766. https://doi.org/10.1016/j.nantod.2019.100766
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: Principles, delivery, and clinical translation. Nature Reviews Drug Discovery, 20, 817–838. https://doi.org/10.1038/s41573-021-00283-5
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
Jin, L., Zhou, Y., Zhang, S., & Chen, S. J. (2025). mRNA vaccine sequence and structure design and optimization: Advances and challenges. Journal of Biological Chemistry, 301(1), 108015. https://doi.org/10.1016/j.jbc.2024.108015
Wilson, E., Goswami, J., Baqui, A. H., et al. (2023). Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. New England Journal of Medicine, 389(24), 2233–2244. https://doi.org/10.1056/NEJMoa2307079
International AIDS Vaccine Initiative (IAVI). Two HIV Vaccine Trials Show Proof of Concept
Li, J., Liu, Q., Liu, J., Wu, X., Lei, Y., Li, S., Zhao, D., et al. (2022). An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs. Virology Journal, 19(1), 184. https://doi.org/10.1186/s12985-022-01919-7
Fang, Z., Yu, P., & Zhu, W. (2024). Development of mRNA rabies vaccines. Human Vaccines & Immunotherapeutics, 20(1), 2382499. https://doi.org/10.1080/21645515.2024.2382499
Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., et al. (2023). From bench to bedside: Implications of lipid nanoparticle carrier reactogenicity for advancing nucleic acid therapeutics. Pharmaceuticals, 16(8), 1088. https://doi.org/10.3390/ph16081088
British Medical Journal (BMJ) Response Archive
World Health Organization (WHO). Pharmacovigilance
Centers for Disease Control and Prevention (CDC). Myocarditis and Pericarditis after COVID-19 Vaccination
Yaremenko, A. V., Khan, M. M., Zhen, X., Tang, Y., & Tao, W. (2025). Clinical advances of mRNA vaccines for cancer immunotherapy. Med, 6(1), 100562. https://doi.org/10.1016/j.medj.2024.11.015
Saxena, S., Mandrah, V., Tariq, W., Das, P., Sambhav, K., & Devi, S. H. (2025). The future of mRNA vaccines: Potential beyond COVID-19. Cureus, 17(5), e84529. https://doi.org/10.7759/cureus.84529
%20Formation,%20Delivery%20Mechanism,%20Microfluidic%20Mixing%20&%20Therapeutic%20Applications.png)
